ORIC Pharmaceuticals Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
119
- Stock Symbol
-
ORIC
- Share Price
-
$7.35
- (As of Friday Closing)
ORIC Pharmaceuticals General Information
Description
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Contact Information
Website
www.oricpharma.comCorporate Office
- 240 East Grand Avenue
- 2nd Floor
- South San Francisco, CA 94080
- United States
Corporate Office
- 240 East Grand Avenue
- 2nd Floor
- South San Francisco, CA 94080
- United States
ORIC Pharmaceuticals Timeline
ORIC Pharmaceuticals Stock Performance
As of 20-Nov-2026, ORIC Pharmaceuticals’s stock price is $7.35. Its current market cap is $765M with 104M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.35 | $7.70 | $7.23 - $14.68 | $765M | 104M | 1.58M | -$1.47 |
ORIC Pharmaceuticals Financials Summary
As of 30-Sep-2026, ORIC Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,134,765 | 512,805 | 300,227 | 277,309 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (154,707) | (128,248) | (126,740) | (99,665) |
| Net Income | (155,840) | (129,468) | (127,847) | (100,697) |
| Total Assets | 366,886 | 408,890 | 274,142 | 252,007 |
| Total Debt | 3,352 | 3,330 | 3,183 | 2,752 |
ORIC Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ORIC Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
ORIC Pharmaceuticals Comparisons
Industry
Financing
Details
ORIC Pharmaceuticals Competitors (85)
One of ORIC Pharmaceuticals’s 85 competitors is ImmunityBio, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Mustang Bio | Formerly VC-backed | Waltham, MA | ||||
| Evotec | Formerly PE-Backed | Hamburg, Germany | ||||
| Agios Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Celldex | Formerly VC-backed | Hampton, NJ |
ORIC Pharmaceuticals Patents
ORIC Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236194-A1 | Treatment of breast cancer | Pending | 06-May-2025 | ||
| WO-2026217890-A1 | Compounds for use in the treatment of cancer | Pending | 11-Apr-2025 | ||
| WO-2026217431-A1 | Treatment of lung cancer | Pending | 07-Apr-2025 | ||
| WO-2026207203-A1 | Treatment of colorectal cancer | Pending | 27-Mar-2025 | ||
| WO-2026207077-A1 | Pharmaceutical compositions comprising an inhibitor of egfr | Pending | 26-Mar-2025 | A61K9/2054 |
ORIC Pharmaceuticals Signals
ORIC Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ORIC Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 08, 2026
37.37 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
ORIC Pharmaceuticals FAQs
-
When was ORIC Pharmaceuticals founded?
ORIC Pharmaceuticals was founded in 2014.
-
Where is ORIC Pharmaceuticals headquartered?
ORIC Pharmaceuticals is headquartered in South San Francisco, CA.
-
What is the size of ORIC Pharmaceuticals?
ORIC Pharmaceuticals has 119 total employees.
-
What industry is ORIC Pharmaceuticals in?
ORIC Pharmaceuticals’s primary industry is Drug Discovery.
-
Is ORIC Pharmaceuticals a private or public company?
ORIC Pharmaceuticals is a Public company.
-
What is ORIC Pharmaceuticals’s stock symbol?
The ticker symbol for ORIC Pharmaceuticals is ORIC.
-
What is the current stock price of ORIC Pharmaceuticals?
As of 20-Nov-2026 the stock price of ORIC Pharmaceuticals is $7.35.
-
What is the current market cap of ORIC Pharmaceuticals?
The current market capitalization of ORIC Pharmaceuticals is $765M.
-
Who are ORIC Pharmaceuticals’s competitors?
ImmunityBio, Mustang Bio, Evotec, Agios Pharmaceuticals, and Celldex are some of the 85 competitors of ORIC Pharmaceuticals.
-
What is ORIC Pharmaceuticals’s annual earnings per share (EPS)?
ORIC Pharmaceuticals’s EPS for 12 months was -$1.47.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process